These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy. Paton DM Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578 [TBL] [Abstract][Full Text] [Related]
3. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells. Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660 [TBL] [Abstract][Full Text] [Related]
4. New and developing therapies in spinal muscular atrophy. Kariyawasam D; Carey KA; Jones KJ; Farrar MA Paediatr Respir Rev; 2018 Sep; 28():3-10. PubMed ID: 29703692 [TBL] [Abstract][Full Text] [Related]
5. Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease. Rao VK; Kapp D; Schroth M J Manag Care Spec Pharm; 2018 Dec; 24(12-a Suppl):S3-S16. PubMed ID: 30582825 [TBL] [Abstract][Full Text] [Related]
6. Moving towards treatments for spinal muscular atrophy: hopes and limits. Wirth B; Barkats M; Martinat C; Sendtner M; Gillingwater TH Expert Opin Emerg Drugs; 2015 Sep; 20(3):353-6. PubMed ID: 25920617 [TBL] [Abstract][Full Text] [Related]
7. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape. Wood MJA; Talbot K; Bowerman M Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438 [TBL] [Abstract][Full Text] [Related]
9. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. Finkel RS; Mercuri E; Darras BT; Connolly AM; Kuntz NL; Kirschner J; Chiriboga CA; Saito K; Servais L; Tizzano E; Topaloglu H; Tulinius M; Montes J; Glanzman AM; Bishop K; Zhong ZJ; Gheuens S; Bennett CF; Schneider E; Farwell W; De Vivo DC; N Engl J Med; 2017 Nov; 377(18):1723-1732. PubMed ID: 29091570 [TBL] [Abstract][Full Text] [Related]
10. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy. d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471 [TBL] [Abstract][Full Text] [Related]
11. Nusinersen in the Treatment of Spinal Muscular Atrophy. Goodkey K; Aslesh T; Maruyama R; Yokota T Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535 [TBL] [Abstract][Full Text] [Related]
12. Nusinersen: A Review in 5q Spinal Muscular Atrophy. Hoy SM CNS Drugs; 2018 Jul; 32(7):689-696. PubMed ID: 30027400 [TBL] [Abstract][Full Text] [Related]
13. Investigation of New Morpholino Oligomers to Increase Survival Motor Neuron Protein Levels in Spinal Muscular Atrophy. Ramirez A; Crisafulli SG; Rizzuti M; Bresolin N; Comi GP; Corti S; Nizzardo M Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316633 [TBL] [Abstract][Full Text] [Related]
14. Systemic and ICV Injections of Antisense Oligos into SMA Mice and Evaluation. Aslesh T; Maruyama R; Yokota T Methods Mol Biol; 2018; 1828():455-465. PubMed ID: 30171559 [TBL] [Abstract][Full Text] [Related]
15. Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients. Bianchi L; Sframeli M; Vantaggiato L; Vita GL; Ciranni A; Polito F; Oteri R; Gitto E; Di Giuseppe F; Angelucci S; Versaci A; Messina S; Vita G; Bini L; Aguennouz M Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919289 [TBL] [Abstract][Full Text] [Related]
16. Advances in therapy for spinal muscular atrophy: promises and challenges. Groen EJN; Talbot K; Gillingwater TH Nat Rev Neurol; 2018 Apr; 14(4):214-224. PubMed ID: 29422644 [TBL] [Abstract][Full Text] [Related]
17. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy. Singh NN; Lee BM; DiDonato CJ; Singh RN Future Med Chem; 2015; 7(13):1793-808. PubMed ID: 26381381 [TBL] [Abstract][Full Text] [Related]
18. Bridging the Gap: Gene Therapy in a Patient With Spinal Muscular Atrophy Type 1. Costamagna G; Govoni A; Wise A; Corti S Neurology; 2022 Nov; 99(21):952-956. PubMed ID: 36319109 [TBL] [Abstract][Full Text] [Related]
19. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration. Arnold WD; Duque S; Iyer CC; Zaworski P; McGovern VL; Taylor SJ; von Herrmann KM; Kobayashi DT; Chen KS; Kolb SJ; Paushkin SV; Burghes AH PLoS One; 2016; 11(12):e0167077. PubMed ID: 27907033 [TBL] [Abstract][Full Text] [Related]